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Publicly available data can potentially examine the relationship between environmental exposure 46 
and public health, however, it has not yet been widely applied. Arsenic is of environmental 47 
concern, and previous studies mathematically parameterized exposure duration to create a link 48 
between duration of exposure and increase in risk. However, since the dose metric emerging from 49 
exposure duration is not a linear or explicit variable, it is difficult to address the effects of exposure 50 
duration simply by using mathematical functions. To relate cumulative dose metric to public health 51 
requires a lifetime physiologically-based pharmacokinetic (PBPK) model, yet this model is not 52 
available at a population level. In this study, the data from the U.S. total diet study (TDS, 53 
2006-2011) was employed to assess exposure: daily dietary intakes for total arsenic (tAs) and 54 
inorganic arsenic (iAs) were estimated to be 0.15 and 0.028 µg/kg/day, respectively. Meanwhile, 55 
using National Health and Nutrition Examination Survey (NHANES, 2011-2012) data, the fraction 56 
of urinary As(III) levels (geometric mean: 0.31 µg/L) in tAs (geometric mean: 7.75 µg/L) was 57 
firstly reported to be approximately 4%. Together with Bayesian technique, the assessed exposure 58 
and urinary As(III) concentration were input to successfully optimize a lifetime population PBPK 59 
model. Finally, this optimized PBPK model was used to derive an oral reference dose (Rfd) of 0.8 60 
µg/kg per day for iAs exposure. Our study also suggests the previous approach (by using 61 
mathematical functions to account for exposure duration) may result in a conservative Rfd 62 
estimation.  63 
KEY WORDS： PBPK model; Dose response; Bayesian Simulation; Arsenic; Publicly 64 
Available data 65 
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1. Introduction 68 
Chronic exposure to elevated levels of arsenic (As) has resulted in many adverse effects 69 
appearing in humans (Maull et al. 2012; Naujokas et al. 2013). Epidemiological evidence 70 
provides opportunities to undertake a dose-response study, and furthermore to assist in 71 
assessment and management. For example, one study over a mean follow-up period of 9.7 72 
years for 52,931 eligible participants suggested that the adjusted incidence rate ratios per 1 73 
μg/L increment in arsenic levels in drinking water were 1.03 (95% confidence interval (CI): 74 
1.01, 1.06) for all diabetes cases (Bräuner et al. 2014). Such epidemiological studies have 75 
convincingly linked the As exposure level and risk (Bräuner et al. 2014; U.S. EPA 1988).  76 
 77 
Excepting exposure level, previous research has also demonstrated the incidence of 78 
diseases increases with exposure duration (Liao et al. 2008; Mazumder et al. 1998; U.S. 79 
EPA 1988). To quantify the exposure duration effects, mathematical functions (such as 80 
Weibull and Hill functions) have usually been employed, by parameterizing age factor to 81 
represent exposure duration effect (Liao et al. 2008; U.S. EPA 1988). For long-term 82 
chronic exposure, since the dose metric emerging from exposure duration is not a linear or 83 
explicit variable, it is difficult to address these effects simply based on mathematical 84 
parameterization (Hodgson and Darnton 2000; Philippe and Mansi 1998). The case study 85 
on dioxin has successfully illustrated how to use toxicokinetic model to convert external 86 
exposure level and exposure duration into a cumulative dose metric, which was further 87 
applied in dose-response study (Becher et al. 1998; Crump et al. 2003). To understand the 88 
influence of exposure duration to public health requires a toxicokinetic model to 89 
appropriately quantify the impact of exposure duration on delivered dose and ultimately 90 
risk in a quantitative dose-response framework.  91 
 92 
Several toxicokinetic models have been previously developed (El-Masri and Kenyon 2008; 93 
Liao et al. 2008; Yu 1999). Based on short-term oral exposures, Yu (1999) developed a 94 
seven-compartment physiologically-based pharmacokinetic (PBPK) model for inorganic 95 
As (iAs). More recently, El-Masri and Kenyon (2008) published an individual PBPK 96 
model that traced the relationships among iAs, monomethylarsenic acid (MMA) and 97 
dimethylarsenic acid (DMA) for oral exposure. While these models offered an overview of 98 
the absorption, metabolism, distribution and excretion mechanisms in human systems, all 99 
such models were developed based on normal people at an individual level. To relate 100 
exposure to public health, a PBPK model needs to account for intrinsic heterogeneity at a 101 
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population and lifetime scale. 102 
 103 
Publicly available data have the potential to support the optimization of population PBPK 104 
models for use in quantitative risk assessment (Bernillon and Bois 2000; Lyons et al. 2008), 105 
particularly in dose-response study. Specifically, the U.S. FDA has conducted a total diet 106 
study (TDS) program to monitor the levels of multiple elements, as well as As, in the 107 
country’s food supply (Tao and Michael Bolger 1999). Also, the National Health and 108 
Nutrition Examination Survey (NHANES) program was initiated to assess the health and 109 
nutritional status of adults and children in the United States (Aylward et al. 2014). Fitting of 110 
PBPK models to available data using Bayesian methods such as Markov Chain Monte 111 
Carlo (MCMC), these publicly available data can be utilized to bridge As exposure and 112 
public health. To the best of our knowledge, this type of research has not previously been 113 
attempted and represents a novel interpretation of human health from existing data sets. 114 
 115 
In this study, the aim is to illustrate how to integrate publicly available data, PBPK model 116 
and Bayesian simulation to refine human health risk assessment, using arsenic as a case 117 
study. In particular, the objectives include: 1) assessment of As exposure from U.S. TDS; 2) 118 
reporting As biomonitoring information based on the latest U.S. NHANES data 119 
(2011-2012); 3) optimizing an As population lifetime PBPK model; and 4) improving As 120 
non-cancer dose-response study. The newly proposed dose-response study has the potential 121 
to protect human health from arsenic exposure.  122 
2. Materials and Methods  123 
2.1. Procedure for Establishing Arsenic Dose Response.  124 
As shown in Figure 1, the procedure for establishing As dose response consisted of three 125 
steps. In step 1, a national As exposure assessment was conducted based on TDS data. Then, 126 
the urinary As data was retrieved from NHANES database. The As exposure information 127 
and urinary As concentration were set as PBPK model input and output, respectively. 128 
Therefore a population, lifetime PBPK model was optimized by using Bayesian simulation 129 
(step 2). Finally, the optimized PBPK model assisted in As dose-response study (step 3).  130 
 131 
2.2. Exposure Assessment.  132 
The U.S. FDA has released analytical results for samples (all the samples in the TDS study 133 
were table-ready prior to analysis) collected during 2006-2011 for toxic and nutritional 134 
elements (U.S. FDA 2014). The total As concentrations (tAs) in 272 types of foods were 135 
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also measured. The foods were collected based on the food list representing the major 136 
components of American people’s diet. In the meantime the U.S. FDA compiled food 137 
consumption data from 9 age subgroups (U.S. FDA 2009). Therefore, the daily tAs 138 
exposure (EAs) was estimated by multiplying arsenic concentration (CAs) and the 139 
age-specific consumption amount (AAs) for each TDS food: 140 
As As AsE =C A×       (1) 141 
In this study, all 272 types of food were classified into six categories: seafood (exclude 142 
fish), rice/bread/wheat, fish, vegetables, meat, wine and others.  143 
 144 
Only tAs was available in the current TDS study. Lynch et al. (2014) have evaluated the 145 
iAs fraction of tAs in food based on more than 6500 data points. To our knowledge, their 146 
research is the most comprehensive available analysis on arsenic forms in food. Thus, the 147 
fractions of iAs in different food categories were summarized in this study (Supplementary 148 
Material(SM) Table S1), and were used to estimate daily exposure for different forms of As 149 
in each food category.  150 
 151 
Excepting diet exposure, drinking water was also deemed to be an important pathway for 152 
iAs exposure. Xue et al. (2010) have estimated that the daily iAs exposure from drinking 153 
water was 0.025±0.104 µg/kg.bw per day (median: 0.002 µg/kg.bw per day) for the U.S. 154 
population. Consequently this median value was considered to be geometric mean (GM) of 155 
drinking water exposure to help estimate arsenic exposure.  156 
 157 
In this study, a log-normal distribution (LN) of daily intake was employed to account for 158 
population variability: 159 
As-Individual E ( , )LN GM GSD�    (2) 160 
The median value of daily arsenic intake (the sum of dietary exposure and drinking water) 161 
was used to represent the GM of this log-normal distribution, and the geometric standard 162 
deviation (GSD) of iAs intake was estimated to be 1.58, which was based on a previous 163 
survey of the general U.S. population (Yost et al. 2004). 164 
 165 
2.3. Biomonitoring Data.  166 
The urinary biomarker data, including the tAs, iAs, MMA, DMA, arsenobetaine and 167 
arsenocholine was derived from the NHANES (n=4794) (NHANES 2014). The detection 168 
rates for tAs, As(III), As(V), MMA, DMA, arsenobetaine, arsenocholine and 169 
 8 
trimethylarsine oxide were 96%, 31%, 3%, 27%, 80%, 47%, 4% and 2%, respectively. A 170 
log-normal distribution was assumed for urinary concentrations (Aylward et al. 2014), and 171 
the maximum likelihood estimation (MLE) was performed to obtain the statistical 172 
parameters, including the GM and GSD.  173 
 174 
2.4. PBPK Model.  175 
Our PBPK model was derived from previous studies (El-Masri and Kenyon 2008; Liao et 176 
al. 2008; Yu 1999). Compared to prior models, this model allowed a lifetime exposure by 177 
specifying some age-dependent parameters (Table 1). This human PBPK was a 178 
five-compartment model consisting of four well-mixed tissue groups—liver, kidney, lung, 179 
and rest of the body—and a mixed blood compartment (Figure 1). A detailed description of 180 
the PBPK model and the programming code is available in the SM.  181 
 182 
To account for the population variability of current lifetime PBPK model, three strategies  183 
were used: firstly, the Gaussian distribution families were assumed for physiological 184 
parameters (30% relative standard derivation (RSD) was used (Dong and Hu 2011), the 185 
means of theses Gaussian distributions have been provided in Table 1); secondly, a 186 
population optimization for sensitive parameters was performed based on a Bayesian 187 
hierarchical model (BHM) (Lyons et al. 2008; Wan et al. 2013): to select the sensitive 188 
parameters, a prior sensitivity analysis was carried out and the results were shown in Table 189 
S2. Consequently, three parameters, i.e. liver/blood partition coefficients for As(III), 190 
maximum metabolism rate constant for As(III)-MMA, urinary elimination constants for 191 
As(III), were outlined as the sensitive parameters for optimization. Thirdly, a log-normal 192 
distribution for daily exposure was adopted (as described in the earlier section).  193 
 194 
2.5. Bayesian Simulation.  195 
A BHM was established to estimate the sensitivity parameters as shown in Figure 1. 196 
Predicted urinary levels (PULs) through the PBPK model by inputting the sensitive 197 
parameters (Ps), exposure time (t) and other model parameters (Φ), and then PULs and 198 
observed urinary levels (MULs) were linked through a residual error model (log-normal 199 
distribution) with the mean (zero) and variance (σ2) in the likelihood calculation (Yang et al. 200 
2010). Considering reported As exposure information did not distinguish the specifications 201 
of organic arsenic (MMA, DMA, arsenobetaine and arsenocholine), correspondingly we 202 
 9 
cannot employ the urinary organic arsenic (oAs) concentrations as the MULs in this study. 203 
In contrast, we selected urinary As(III) levels as the MULs as the detection rate for As(V) 204 
was too low (3%) to derive reliable statistics for As(V) (NHANES 2014).  205 
 206 
Corresponding to Bayesian theory, the estimated posterior probability density function 207 
(PPDF) for target parameters was obtained from the product of the joint prior probability 208 
density function (pPDF) and the likelihood function. This was done based on the 209 
measurement model describing the difference between the model simulation and the 210 
observation (Lyons et al. 2008; Sohn et al. 2004). A joint prior probability distribution was 211 
encoded as 2 2( , ) ( ) ( )s sp P p p Ps s= × . Hence, the PPDF for 2s and sP  can be expressed by 212 
Equation (3): 213 
2 22 ,( , ) ( ) ( ) ( )s MULs MULs s sP P C p C P p P ps s s∝ × ×    (3)  214 
The prior distributions were non-informative for p( 2s ) (a uniform distribution with 215 
boundary of 0.001-100) and p( sP ) (normal distributions with 500% RSDs, the prior means 216 
of these normal distributions have been noted in Table 1). With the prior distributions 217 
for sP and 2s , the residual error model used in the likelihood function for different age 218 
groups (i=1~6) was expressed as Equation (4): 219 
n( ) n( ( , , )) n( )s i s iMUT s i PUT iL C L f P t L Cε ε− −= Φ + = +   (4) 220 
where iε  was the error in age group i, which was termed 
2(0, )i Nε s�  and f expressed 221 
the PBPK model. With the prior distribution for 2s , the posterior distribution for the 222 
parameters of interest was calculated by applying Equation (4) in the likelihood function 223 




( ) ( )MULs s MULs i PULs i s
i
p C P p C C Ps − −
=
∝∏     (5) 225 
In this log-normal measurement model, 96 individuals (I) were chosen (Dong and Hu 2011) 226 
due to the computational time required (approximate 90mins for each individual). MCMC 227 
computation was used to optimize the parameters. The Gibbs and Metropolis Hastings (MH) 228 
samplers were used to update the object parameters (Xu et al. 2006): 1) the parameter, 2s , 229 
was randomly drawn from the inverse gamma distribution by using the Gibbs sampler; 2) 230 
the conditional distributions for Ps have no specific form as the PBPK model is non-linear, 231 
and therefore we sampled the Ps by using the Metropolis algorithm. 232 
 233 
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2.6. Dose-Response Assessment.  234 
Several symptoms have been considered to associate with ingested iAs (Bräuner et al. 2014; 235 
Liao et al. 2008), while the skin lesions are considered as the most common symptoms. 236 
Thus, the skin lesions of keratosis and hyperpigmentation were selected as the critical 237 
non-cancer effects for As exposure in this study. Between April 1995 and March 1996, a 238 
survey was conducted to investigate these two effects in West Bengal, India (Mazumder et 239 
al. 1998). In all, 7683 participants were examined and interviewed, and the As levels in 240 
drinking water were measured (Mazumder et al. 1998). The As levels and age were divided 241 
into eight groups (0-50, 50-99, 100-149, 150-199, 200-349, 350-49, 500-799, and 800+ 242 
µg/L) and seven age groups (<9, 10-19, 20-29, 30-39, 40-49, 50-59, 60+), respectively 243 
(Mazumder et al. 1998). Using the established PBPK model, drinking water iAs 244 
concentration (Cw) was converted into urinary iAs concentration (UCiAs), and then 245 
cumulative urinary concentration (CUC) was estimated by integrating UCiAs and age (t):  246 
, , ,w(C )iAs sUC f P t= Φ     (6) 247 
0
t
iAsCUC UC dt= ∫       (7) 248 
In our study, since previous studies indicated that the skin lesions were associated to 249 
As-contaminated drinking water and drinking water was considered as major exposure 250 
pathway (Bagla and Kaiser 1996; Mandal 1996; Mazumder et al. 1998), only drinking 251 
water pathway was included when conducting dose-response study.  252 
 253 
Then, the benchmark dose (BMD) approach was employed to estimate the iAs BMD and 254 
the lower 95% confidence limit of BMD (BMDL) of the CUC (Davis et al. 2011; Wheeler 255 
and Bailer 2009), and finally the BMDLCUC was extrapolated as the reference dose (Rfd). 256 
To minimize model uncertainties, seven BMD models were included in this estimation, 257 
including Gamma, Dichotomous-Hill, Logistic, Log-logistic, Probit, Logprobit and Weibull 258 
models (Davis et al. 2011). 259 
3. Results and Discussion 260 
3.1. Exposure Estimation. 261 
Of the 272 types of food, only the median value of 24 types were above the detection limit 262 
(U.S. FDA 2014). Together with consumption data (U.S. FDA 2009), the median of daily 263 
dietary tAs exposure was estimated to be 0.15 µg/kg/day (body weight was used as 70 kg). 264 
Specifically, the values for age groups 0 - 0.5, 2, 6, 10, 14 - 16, 25 - 30, 40 - 45, 60 - 65, 70+ 265 
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were 0.24, 0.39, 0.19, 0.18, 0.15, 0.16, 0.15, 0.20 and 0.16 µg/kg/day, respectively (Figure 2, 266 
age-specific body weights as presented in Table 1 were used here). These age groups were 267 
identical to the classification of age groups by U.S. Food and Drug Administration (U.S. FDA 268 
2009). For young children (<6 years of age), the tAs exposure from food was approximately 269 
1.5 - 2 times higher than that shown for other groups. Figure 2 also identified that the highest 270 
contribution to tAs is made by seafood (58.46%, excluded fish), followed by rice/bread/wheat 271 
(22.82%) and fish (14.72%).  272 
 273 
The median value of estimated daily dietary iAs intake was 0.028 µg/kg/day for all age 274 
groups. In particular the daily dietary intakes for As(III) and As(V) were estimated to be 0.020 275 
and 0.0077 µg/kg/day, respectively. Thus, it was concluded that approximately 18.67% of tAs 276 
exposure originating from diet was toxic iAs. Specifically, the iAs percentages for age groups 277 
0 - 0.5, 2, 6, 10, 14 - 16, 25 - 30, 40 - 45, 60 - 65, 70+ were 40.67%, 27.56%, 27.37%, 21.34%, 278 
22.19%, 21.44%, 19.43%, 12.76% and 12.38%, respectively. Thus, age differences were 279 
observed (Figure 2): young children’s daily intake of iAs daily can be up to 0.11 µg/kg/day, 280 
which was approximately 4 times higher than older age groups. However, the major 281 
contribution to iAs exposure arose from rice/bread/wheat (84% for As(III) and 72% for 282 
As(V)), while the rice/bread/wheat only contributed 23% to tAs exposure. Such differences 283 
can be explained by the iAs fraction in food commodities (Table S1): although seafood made 284 
the biggest contribution to tAs intake, the iAs fraction in seafood was approximately 1.2%. 285 
Thus, seafood only contributed 3.66% and 5.38% for As(III) and As(V), respectively. On the 286 
other hand, the fractions of As(III) and As(V) in the rice/bread/wheat were up to 49.01% and 287 
15.99%, respectively.  288 
 289 
Estimations in current study showed agreement with the urinary excretion: considering the 290 
median value for tAs in urine for the general U.S. population was reported to be 8.15 µg/L 291 
(Aylward et al. 2014), the daily intake should be approximately 12.68 µg/day. This is 292 
assuming the urine volume is about 1.4 L per day and 90% of excretion was estimated by 293 
urine (Pomroy et al. 1980): 8.15×1.4/90%=12.68 µg/day. Our dietary tAs exposure estimation 294 
was 10.5 µg/day (0.15 µg/kg/day × 70 kg=10.5 µg/day), which is close to the total intake 295 
amount of 12.68 µg/day. This estimation also indicated dietary is a major pathway, which has 296 
been demonstrated in previous studies (MacIntosh et al. 1996; Yost et al. 2004).  297 
 298 
Previous studies have reported daily arsenic exposure in the general U.S. population 299 
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(MacIntosh et al. 1997; Xue et al. 2010; Yost et al. 2004). For example, MacIntosh et al. 300 
(1997) have reported that the mean dietary intake of tAs was 1.56 µg/kg/day (assuming an 301 
adult weight of 70 kg), which was much higher than the median value (0.15 µg/kg/day) in this 302 
report. Yost et al. (2004) estimated that for children the tAs exposure was 3.2 µg/day on 303 
average, with a range of 1.6~6.2 µg/day, which was similar to the estimations in this study. 304 
More recently, using data from 2003-2004 NHANES individual data, the median estimations 305 
for tAs and iAs were 0.08 µg/kg/day and 0.02 µg/kg/day, respectively (Xue et al. 2010). 306 
Comparing to the estimation for tAs in this study (median: 0.15 µg/kg/day), the estimation for 307 
tAs was 2~3 times lower in the previous study (Xue et al. 2010).  308 
 309 
Another difference between current study and the previous one is the contributions of food 310 
commodities (Xue et al. 2010). One prior analysis showed that rice, wheat and related 311 
products contributed about 29% of the iAs intake (Xue et al. 2010), which was much lower 312 
than an estimation of 80.68% in this study. An estimation of only 24.32% iAs fraction in rice 313 
(Schoof et al. 1999), which was adopt in previous study (Xue et al. 2010) and then resulted in 314 
a low contribution being made by rice/bread/wheat. Contrastingly, a board array of literature 315 
indicated that iAs fraction in rice was up to 65% (Jorhem et al. 2008; Lynch et al. 2014; 316 
Torres-Escribano et al. 2008). Ancillary support provided by the European Food Safety 317 
Authority also suggested that on average iAs represents approximately 70% of the tAs content 318 
in rice, except for brown rice where on average iAs represents around 80% of tAs content 319 
(EFSA 2014). Thus, previous report may underestimate the contribution of iAs from 320 
rice/bread/wheat since it adopt a lower iAs fraction in rice/bread/wheat (Xue et al. 2010). 321 
 322 
The iAs exposure from drinking water was estimated to be 0.002~0.004 µg/kg/day at a 323 
national survey previously (Xue et al. 2010), which was referred to include drinking water to 324 
calculate arsenic daily exposure in this study. 325 
3.2. Urinary Arsenic Concentrations. 326 
Of all the biomarkers examined for As exposure in the NHANES subjects (n=4794), the GM 327 
and GSD were estimated to be 7.75 µg/L and 3.14, respectively (Table 2). Specifically, DMA 328 
and arsenobetaine had relatively high concentrations, with GM of 3.85 µg/L and 1.66 µg/L, 329 
respectively, followed by MMA (0.55 µg/L) and As(III) (0.36 µg/L). The age trend for As(III) 330 
concentrations has also been statistically analysed (Table 2): the mean As(III) concentrations 331 
for age groups 6-9, 10-15, 16-29, 30-44, 45-64 and 65+ were 0.44, 0.49, 0.50, 0.50, 0.40 and 332 
0.33 µg/L, respectively.  333 
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 334 
This study marks the first one to document As(III) concentration in the general U.S. 335 
population. For 2011-2012 NHANES data, the detection limit for As(III) declined sharply 336 
from 1.2 µg/L (2009-2010 NHANES) to 0.48 µg/L (2011-2012 NHANES). Thus, the 337 
detection rate increased from <5% to 31%, which provided an opportunity to estimate As(III) 338 
concentration in general population. Based on a log-normal assumption for As(III), the As(III) 339 
concentration using MLE methods was evaluated. A previous study stated that the MLE 340 
method has an acceptable error ratio (0.7%), and further simulation indicated that only when 341 
the detection rate fell below 25%, did the error ratio dose differ from zero (Croghan and 342 
Egeghy 2003). In this study the impact of low detection rate was also simulated (Matlab 343 
pseudocode is provided in the SM). The simulated results showed the error ratio was below 344 
5% (detection rate>30%) when the size was 4794 (the population size in this study), which 345 
suggested our estimated As(III) may be reliable. 346 
 347 
Aylward et al. (2014) observed that the secondary methylation index (SMI, ratio of urinary 348 
DMA to MMA) in the NHANES program likewise is much higher in people with measurable 349 
arsenobetaine than in those without, suggesting that direct DMA exposure is co-occurring 350 
with exposure to arsenobetaine. Such study indicated correlations among urinary DMA, 351 
MMA, and arsenobetaine may potentially characterize source exposure (Aylward et al. 2014). 352 
Figure 3(d) illustrates a relationship between DMA and MMA 353 
(Ln(DMA)=1.04×Ln(MMA)+1.83, n=1280, p<0.0001), may indicate direct exposure to these 354 
species in seafood or the metabolism of organic arsenicals. Previous analyses did not correlate 355 
As(III) and organic arsenic at the national scale due to As(III) concentration was not available. 356 
In this study, Figure 3(a)-(c) stated there were significant log-log linear regressions between 357 
As(III) and tAs, MMA and DMA. The correlations between As(III) and MMA 358 
(Ln(MMA)=0.55×Ln(As(III))+0.48; r2=0.35, n=944, p<0.001) were apparently more 359 
significant than those between As(III) and DMA (Ln(DMA)= 0.87×Ln(As(III))+2.27; r2=0.27, 360 
n=1480, p<0.001). This can be explained by the metabolism from MMA to DMA, which 361 
would amplify the heterogeneities when addressing the relationship between As(III) and 362 
DMA. Such heterogeneities were also propagated when linking As(III) and tAs, which would 363 
reduce the fit (Figure 3(a), Ln(tAs)= 1.04×Ln(As3)+3.06; r2=0.19, n=1486, p<0.001). These 364 
correlations may help trace arsenic exposure in the future.  365 
 366 
3.3. PBPK Model Optimisation.  367 
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Although nine age groups were used in the TDS, the youngest participant in the NHANES 368 
program was 6 years old. Therefore, the daily exposure estimations for the six age groups (as 369 
listed in Table 2) were identical to average exposures of (6 yrs, 10 yrs), (10 yrs, 14-16 yrs), 370 
(14-16 yrs, 25-30 yrs), (25-30 yrs, 40-45 yrs), (40-45 yrs, 60-65 yrs), and (60-65 yrs, 70 yrs), 371 
respectively. The Gelman-Rubin diagnostic method served to test the convergence of the 372 
objective  parameters (Dong and Hu 2011) and was achieved in this study. The posterior 373 
distribution for the three sensitive parameters, including the liver/blood partition coefficient 374 
for As(III), maximum metabolism rate constant for As(III)-MMA, and the urinary elimination 375 
constant for As(III), were estimated to be 20.93 ± 11.33 (95%CI: 0.95 - 41.19), 5.68×10-7 ± 376 
2.85×10-7 (95%CI: 0.68×10-7- 1.12×10-6) mol/min and 0.098 ± 0.046 (95% CI: 0.019-0.19) 377 
(min-1) (as shown in Table 1), respectively. Comparison with the prior value from previous 378 
literature, increases of 26.79% and 9.23% were found for liver/blood partition coefficient and 379 
maximum metabolism rate constant for As(III)-MMA, respectively. The increase for 380 
liver/blood partition indicated the As(III) partitioned more in the liver, and the increase for 381 
maximum metabolism rate constant suggested arsenic is more able to achieve maximum 382 
metabolism. On another aspect, the posterior urinary elimination constant, a much higher with 383 
a value of 40% increases (comparing to prior value), suggesting that As (III) was excreted 384 
more readily in urine. 385 
 386 
These parameter updates can be explained by the error between simulation results and 387 
observed values (SM Figure S1). Using prior information, the simulated GM±GSD of As(III) 388 
for the 6-9, 10-15, 16-29, 30-44, 45-64 and 65+ age groups were 0.19±1.91, 0.24±1.91, 389 
0.41±1.86, 0.44±1.83, 0.39±1.85, 0.33±1.83 μg/L, respectively. The simulated concentrations 390 
for 6-9 and 10-15 were 40% lower than the observed values, while those values for other 391 
groups were 17%-50% higher than the observed values (corresponding As(III) levels, i.e. 392 
0.32±2.24, 0.40±1.91, 0.35±2.31, 0.35±2.31, 0.28±2.34, 0.22±2.48 μg/L). By using the 393 
posterior information, the simulated values (GM±GSD) of As(III) for the six age groups were 394 
0.20±2.34, 0.24±2.29, 0.36±2.19, 0.38±2.14, 0.29±2.16, 0.23±2.13 μg/L, respectively. 395 
Generally, the residual error was magnified with the cumulative probability increased due to 396 
the positive skewness of the lognormal distribution. Although the relative differences between 397 
the 6-9 and 10-15 age groups were still up to 0.38 and 0.40, the average difference for the 398 
following four age groups fell to only 0.053, and the overall relative residual sum of squares 399 
(RRSS) decreased from 0.85 to 0.31. Through Bayesian inference, crucial parameters in the 400 
PBPK model were updated based on the prior distributions, further, calibration of the PBPK 401 
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model improved the prediction of biomonitoring data. Therefore, the updated parameters 402 
under the constraints imposed by the model structure, model parameters, and the prior 403 
exposure, represent more responsible population parameters that can be used to better 404 
understand how exposure events are linked.  405 
 406 
3.4. Dose Response Assessment.  407 
The drinking water iAs concentration and age were inputted into the established PBPK model 408 
to estimate CUC (Equations 4-5). The data for females and males subjects were combined 409 
since the PBPK model did not treat the genders separately. Overall incidences of 410 
hyperpigmentation and keratosis were 4.56% and 2.01%, respectively. Both types of skin 411 
lesions demonstrated a positive age trend, as exemplified the hyperpigmentation incidences 412 
for the age groups <9, 10-19, 20-29, 30-39, 40-49, 50-59, >60 were 1.83%, 2.31%, 4.14%, 413 
5.90%, 7.21%, 9.10% and 7.5%, respectively.  414 
 415 
Table 3 showed the iAs BMD estimation for different models when BMR were set as 10% 416 
and 5%. The estimated iAs BMDL10 ranked from 17.06 - 72.65 µg/kg per day, while the iAs 417 
BMDL5 were estimated with a range of 8.29 - 46.37 µg/kg per day. Using the keratosis as the 418 
critical effect and BMR of 5%, the PoD (Point of Departure) was estimated to be 8.29 µg/kg 419 
per day (the lowest BMDL estimation was used). Since the data for dose-response was only 420 
stemmed from one report, an uncertainty factor of 10 was considered to account for 421 
population variability. Thus, the iAs Rfd was adjusted to be 0.8 µg/kg per day. As stated, 422 
current diet iAs daily intake was estimated to be 0.028 µg/kg/day, which suggested the hazard 423 
quotient (HQ) was only 0.035. Such a low HQ indicated an insignificant risk for skin lesions 424 
when the general U.S. population was exposed to iAs. 425 
 426 
Previous studies also functionally parameterized exposure duration to create a link between 427 
risk increases and exposure duration (Liao et al. 2008; U.S. EPA 1988). Contrastingly, this 428 
study used a PBPK model to include the impacts from exposure duration. For comparisons, 429 
the dose-response data was also analysed using a generalized multistage function to 430 
parameterize exposure duration (U.S. EPA 1988):  431 
2
0 1( , ) 1 exp( ( ( ) )kp duration dose k dose duration k= − − × × −    (8) 432 
where the parameters k0, k1, k2 were skin lesion-specific best-fitted parameters, and model 433 
simulations were provided in SM Table S3, as well as risk-specific dose in SM Table S4. 434 
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Using a response (p in Equation 8) of 5%, the Rfd was estimated to be 0.40 µg/kg per day (for 435 
hyperpigmentation) when considering the intra-specific UF of 10. Thus, our analysis suggests 436 
the previous method may result in a conservative Rfd estimation, since one fold higher Rfd 437 
was obtained when using PBPK model. Moreover, using PBPK model to convert age into a 438 
dose metric not only took into account the cumulative effect, but also simplified the model fit 439 
since it involved fewer variables. A non-straightforward fit will emerge if the models used to 440 
fit dose-response model is too complicated. In fact the Weibull model (Liao et al. 2008), was 441 
also attempted to parameterize the age-effect in our study, however, the simulated results did 442 
not converge (data not shown).   443 
  444 
Arsenic Rfd on humans from epidemiological data was previously evaluated by the U.S. 445 
EPA’s IRIS (U.S. EPA 2012). Using the data from a Taiwanese farming population exposed to 446 
arsenic in well water, a chronic RfD of 0.3 µg/kg/day for inorganic arsenic was derived, based 447 
on a NOAEL of 0.8 µg/kg/day for skin effects and possible vascular complications. However, 448 
the Taiwanese dose-response data is not publicly available currently, which make it is 449 
impossible to implement the estimations and comparisons for this population group.  450 
4. Limitations and Conclusions  451 
Some limitations have been acknowledged in this study. The total exposures considered only diet 452 
and drinking water, since it was difficult to trace other pathways. This treatment may bring the bias 453 
since this value was used as input to optimise the PBPK model parameters. However, previous 454 
studies have demonstrated that diet and drinking water were the major exposures, and such 455 
estimations agree well with the biomonitoring in our analysis. Also, only As(III) was used for 456 
fitting the model parameters and the biomonitoring information for MMA and DMA was discarded: 457 
this modelling endeavour omits MMA and DMA. These arsenic species (MMA and DMA) have 458 
been known to have high activity and are likely the causes of many of even most of arsenic 459 
biological effects (Ahmad et al. 2002; Andrewes et al. 2003). This flaw resulted from that the 460 
details of exposure information on oAs is not available currently. Since oAs is much less toxic than 461 
the inorganic fraction, such a consideration may have limited impact on assessing toxicity. On 462 
another aspect, while cancer may drive the usual arsenic risk assessments, only Rfd based on 463 
non-cancer effect is estimated. This consideration is due to the dose-response data is available for 464 
hyperpigmentation and keratosis, but the raw data for cancer effects cannot be accessed based on 465 
our extensive literature review. Each of these limitations may result in some amount of error or 466 
bias into our study, and more available data promises to overcome these limitations. 467 
 468 
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One major aim of this study is to illustrate how to employ publicly available data inform 469 
environmental regulations. Toward the next generation (NexGen) of human health risk 470 
assessment strategies, new technologies are being used to collect and organize data streams 471 
that promise to reshape our understanding of chemical behaviour (Krewski et al. 2014). By 472 
exchanging such data, more hypotheses, methods and conclusions could benefit both 473 
researchers and stakeholders. For example, current publicly available datasets (such as 474 
ACToR, NHANES, National Morbidity, Mortality, and Air Pollution Study, IRIS) have 475 
largely advanced research on human exposure and health outcomes (Fowler 2013), especially 476 
when examining the links between public health and exposure to a certain chemical as shown 477 
in this study.  478 
 479 
In conclusion, not only did we estimate dietary tAs and iAs exposures for the general U.S. 480 
population, our study is also the first to report that the fraction of As(III) levels in total arsenic 481 
was approximately 4%. Moreover, a population PBPK model was optimised to help derive 482 
iAs Rfd of 0.8 µg/kg per day for skin lesions. The framework presented here illustrates how to 483 
use publicly available data and computational techniques to help stakeholders make informed 484 
decisions. 485 
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TABLE 1. PBPK parameters for arsenic  612 
Parameters Values 
Physiological Parameters (Brown et al. 1997) 
Body Weight (bw) (kg)  0.00059×age3 -0.093×age2 +4.58×age+2.96 
Tissue volume fractions (%) 
     Liver 2.57 
     Kidney 0.44 
     Lung 0.76 
     Others 96.23 
Cardiac Output, QC (L/min) 14.1×bw0.75 
Tissue blood flow fractions (%) 
      Liver 5.96 
      Kidney 19.24 
      Others 74.80 
Partition Coefficients (Benramdane et al. 1999; 
Saady et al. 1989) As3 As5 MMA DMA 
     Liver 20.92a 15.8 3.3 3.3 
     Kidney 11.7 8.3 4.4 3.8 
     Lung 6.7 2.1 1.3 1.3 
     Others 7.3 7.6 2.6 2.4 
Metabolism Parameters (Yu 1999)d As3 to MMA As3 to DMA MMA to DMA 
Maximum metabolism rate 
constant, Vmax (mol/min) 
Liver  5.68×10-7 b 1.04×10-6 7.41×10-7 
Kidney  3.47×10-7 4.63×10-7 2.31×10-7 
Michaelis-Menten constant, Km 
(mol/L) 
Liver  1.00×10-4 1.00×10-4 1.00×10-4 
Kidney  1.00×10-4 1.00×10-4 1.00×10-4 
The other Parameters (Yu 1999) As3 As5 MMA DMA 
Uptake (min-1) 0.004 0.003 0.007 0.007 
Urine elimination (min-1) 0.098c 0.07 0.3 0.13 
Second-order rate (mol-1.min-1) 0.12 
Biliary elimination (min-1) 3.00×10-4 
Absorption fraction (%) 90 
GSH concentration (mol/L) 
      Liver 1.50×10-2 
      Kidney 5.00×10-3 
      Lung 5.00×10-3 
      Others 5.00×10-3 
Most parameters were adopt from previous studies, except the parameters were optimized using Bayesian technique for: a) 613 
liver/blood partition coefficients for As(III), prior mean is 16.5; b) maximum metabolism rate constant for 614 
As(III)-MMA, prior mean is 5.2×10-7; c) urinary elimination constants for As(III), prior mean is 0.07. 615 
 616 
Note: d, the reference values are for 70kg adult, SM Equation 2.617 
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Table 2. Statistical information for arsenic concentration in urine (n=4794) 618 
Basic statistics (µg/L) 
As speciation Detection limit Detection rate (%) GM (GSD) Mean (STD) 
tAs 1.25 96 7.75 (3.14) 14.91 (24.52) 
As(III) 0.48 31 0.31 (2.36) 0.45 (0.47) 
As(V) 0.87 3 NA 
MMA 0.89 27 0.55 (2.15) 0.74 (0.66) 
DMA 1.80 80 3.85 (2.48) 5.82 (6.58) 
Aresenobetaine 1.19 47 1.66 (5.00) 6.06 (21.29) 
Arsenocholine 0.28 4 NA 
Trimethylarsine Oxide 0.25 2 NA 
Age-specific biomonitoring for As(III) (µg/L) 
Age GM (GSD) Mean (STD) 
6-9 0.32 (2.24) 0.44 (0.42) 
10-15 0.40 (1.91) 0.49 (0.36) 
16-29 0.35 (2.31) 0.50 (0.50) 
30-44 0.35 (2.31) 0.50 (0.50) 
45-64 0.28 (2.34) 0.40 (0.41) 
65+ 0.22 (2.48) 0.33 (0.38) 
Abbreviations. tAs: total arsenic; MMA: monomethylarsonic acid; DMA: dimethylarsinic 619 
acid.  620 
621 
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Table 3. Benchmark dose (BMD) estimations (µg/kg/day) using various BMD models for 622 
inorganic arsenic exposure (p>0.1) 623 
  Gamma Hill Logistic Loglogistic Probit Logprobit Weibull 
Hyperpigmentation 
BMD10 58.75 61.68 72.65 58.73 66.77 60.71 58.99 
BMDL10 51.03 49.79 67.22 50.82 61.51 51.22 51.30 
BMD5 30.34 27.17 53.61 30.06 47.77 28.29 30.43 
BMDL5 26.96 22.87 49.58 26.66 44.02 24.86 27.03 
Keratosis 
BMD10 27.10 20.34 51.02 26.53 46.37 25.08 27.10 
BMDL10 24.86 17.06 47.72 24.19 43.32 22.63 24.86 
BMD5 13.21 9.65 34.24 12.58 30.30 11.45 13.21 
BMDL5 12.12 8.29 31.98 11.47 28.31 10.31 12.12 
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Figure 3. Scatter plot for arsenic forms in urine: (a) total arsenic (y) and AsIII (x); (b) 632 
monomethylarsonic acid (y) and AsIII (x); (c) dimethylarsinic acid (y) and AsIII (x); (d) 633 
dimethylarsinic acid (y) and monomethylarsonic acid (x). The data points in red color are 634 
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Figure 3. Scatter plot for arsenic forms in urine: (a) total arsenic (y) and AsIII (x); (b) 648 
monomethylarsonic acid (y) and AsIII (x); (c) dimethylarsinic acid (y) and AsIII (x); (d) 649 
dimethylarsinic acid (y) and monomethylarsonic acid (x). The data points in red color are 650 
considered to be outliers.  651 
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